Novavax, Inc. (NVAX) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call summary presents a mixed picture. While there are positive aspects such as increased demand for Matrix-M and potential milestone earnings from Sanofi, there are concerns about delayed profitability goals and unclear guidance on government stockpiles. The Q&A session revealed optimism about partnerships and technology, but also highlighted uncertainties in timelines and profitability targets. Considering the company's small-cap status, these mixed signals suggest a neutral stock price movement in the short term.
Key Financial Performance
Total Revenue $70 million for Q3 2025, a decrease from $85 million in Q3 2024. The decline is attributed to a change in the business model, focusing on supporting license partners rather than direct commercialization.
Product Sales $13 million for Q3 2025, derived from COVID vaccine and Matrix-M supply sales to license partners. This reflects the shift to a partner-support model.
Licensing, Royalties, and Other Revenue $57 million for Q3 2025, primarily from the Sanofi agreement, including $46 million of R&D reimbursement and $4 million of royalties from Nuvaxovid sales.
Combined R&D and SG&A Expenses $130 million for Q3 2025, an 18% reduction from Q3 2024. SG&A expenses were reduced by 55%, driven by the transition of commercial activities to Sanofi and broader cost reduction efforts.
Net Loss $202 million for Q3 2025, or $1.25 per diluted share. This includes $126 million in noncash charges related to Maryland site consolidation and convertible debt refinancing.
Cash and Accounts Receivable $812 million at the end of Q3 2025, prior to an additional $110 million earned for MAH transfers and Maryland site transactions in Q4.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
New Early-Stage Portfolio: Launched in Q1 2025, includes programs targeting C. diff, shingles, RSV combination, and pandemic flu. Exploration of Matrix-M technology in oncology initiated.
Matrix-M Adjuvant: Expanded partnership with Sanofi to include use in their pandemic flu vaccine candidate. Positive Phase I/II data for combination products featuring Nuvaxovid and flu vaccines.
Sanofi Partnership: Achieved $225 million in milestones for 2025. Sanofi took over lead commercial responsibility for Nuvaxovid in the U.S. and EU, marking a transition year for the product.
Global Vaccine Market: Expected to grow at 6%-8% annually, reaching over $75 billion by 2030. Novavax aims to capitalize on this growth through partnerships and technology.
Cost Reductions: Reduced SG&A expenses by 55% year-over-year in Q3 2025. Consolidated Maryland campus footprint, saving $230 million over 11 years.
Revenue Framework: Raised 2025 revenue framework to $1.040-$1.060 billion. 2026 revenue framework set at $185-$205 million, excluding potential additional revenues.
Shift in Business Model: Transitioned from a single-product focus to a partnership and R&D-driven model. Focus on diversified revenue streams and long-term growth.
Partnerships and Collaborations: Strengthened existing partnerships with Sanofi, Takeda, and Serum Institute. Exploring new collaborations to expand technology applications.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Financial Stability: The company is in a transition phase and has not yet achieved profitability. It is relying on milestone payments and royalties to bridge the gap to profitability, which is expected by 2028. This creates financial uncertainty in the midterm.
Revenue Dependence: The company’s revenue framework heavily depends on partnerships, particularly with Sanofi, and milestone payments. Any delays or failures in these partnerships could significantly impact financial performance.
Regulatory Risks: The company’s future revenue growth is tied to regulatory approvals for new products and programs, such as the Sanofi CIC program. Delays or failures in regulatory processes could hinder growth.
Market Transition: The transition of commercial responsibilities for Nuvaxovid to Sanofi marks a significant shift. If Sanofi fails to execute effectively, it could impact revenue and market presence.
R&D Investment Risks: The company is investing in early-stage R&D programs, which are inherently risky and may not yield successful products or partnerships.
Operational Cost Management: While the company has reduced costs significantly, further cost management is critical to maintain financial stability during this transition phase.
Vaccine Uptake and Market Dynamics: Vaccine confidence and uptake rates vary significantly by region and are influenced by external factors such as political and socioeconomic conditions. This variability could impact the success of the company’s vaccine products.
Supply Chain and Manufacturing: The company is consolidating its Maryland campus and relying on partners for manufacturing and supply chain activities. Any disruptions in these areas could affect operations and financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Framework for 2025: Novavax raised its 2025 revenue framework by $25 million at the midpoint, now expecting adjusted total revenue of $1.040 billion to $1.060 billion. This excludes Sanofi supply sales, royalties, influenza COVID-19 combination, and Matrix-M-related milestones. The increase is driven by higher demand for Matrix-M, increased Sanofi R&D reimbursements, and additional partner revenue.
Revenue Framework for 2026: Novavax expects adjusted total revenue of $185 million to $205 million for 2026. This includes a $75 million milestone for manufacturing technology transfer, $30 million to $40 million in R&D reimbursements, $30 million to $40 million in adjusted supply sales, and $50 million in noncash amortization. Potential additional revenue includes a $125 million milestone for a Phase III CIC program, pending Sanofi's clinical plans.
Profitability Target: Novavax aims to achieve non-GAAP profitability as early as 2028. This is contingent on the successful development and regulatory approval of Sanofi's CIC program, commercial execution by Sanofi, and additional cash flow from new business development agreements.
Sanofi Partnership: Sanofi has taken the lead commercial role for Nuvaxovid in the U.S. and select ex-U.S. markets. Novavax expects significant growth in Nuvaxovid royalties in 2026-2027 as Sanofi builds its marketing and contracting efforts. Sanofi's CIC programs have shown preliminary positive results, and regulatory engagement is planned to advance development.
Early-Stage Pipeline: Novavax is advancing four preclinical vaccine candidates: C. diff, shingles, RSV combination, and pandemic influenza. The company is also exploring the use of its Matrix-M adjuvant in oncology. Early data indicates potential for these programs to address unmet medical needs.
Global Vaccine Market: The global vaccine market is projected to grow at an average annual rate of 6% to 8%, reaching over $75 billion by 2030. Novavax aims to capitalize on this growth by leveraging its technology and expertise.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:How do you see the 2025 COVID season as compared to last year? Are you getting any feedback from pharmacies on stocking and consumer preference for the product?
A:The 2025 COVID season is expected to see a 20% decline in prescriptions compared to last year, attributed to more restrictive policies for below-65 age groups and a one-week delay in the season start. Feedback indicates a resetting of the U.S. COVID market, aligning more with Europe and global markets. The company is optimistic about Sanofi's role in advancing Nuvaxovid.
Q:Could you provide some more color on that BARDA grant? And does it reflect any attitude from the FDA?
A:The BARDA grant was awarded to Sanofi for early-stage work on a pandemic influenza vaccine candidate that includes Novavax's Matrix-M adjuvant. The vaccine is progressing to Phase II, and the company is keen to see results, contributing to pandemic preparedness in the U.S. and globally.
Q:On the Sanofi collaboration, it seems like that's progressing well, including the preliminary positive CIC data they talked about. Could you talk to your awareness and next steps there?
A:Sanofi announced positive data on their combination programs, including their flu vaccines and Nuvaxovid. Novavax is eligible for future royalties and milestones if Sanofi advances to Phase III and markets the product. Novavax intends to outlicense its CIC and flu programs and is in discussions with potential partners.
Q:Where do you stand with your wholly-owned stand-alone flu program?
A:Novavax plans to outlicense its stand-alone flu program, which is Phase III ready, and is seeking partners. The company is optimistic about its technology and its potential impact on global public health.
Q:On the rollout of some of the preclinical data on C. diff, shingles, RSV, were these experiments done with head-to-head comparisons with current available vaccines?
A:Yes, experiments included negative and positive controls, using approved vaccines or constructs similar to competitors' clinical trials. This approach ensures informative and comparative data.
Q:Can you clarify the non-GAAP profitability goal now targeted for 2028?
A:The non-GAAP profitability goal was shifted from 2027 to 2028 due to updated timelines for Sanofi's CIC program. The company is focused on cost control, seeking non-dilutive funding, and leveraging partnerships to achieve profitability.
Q:What is the cadence of timelines and milestones for Matrix-M evaluations with potential partners?
A:Matrix-M evaluations involve lab experiments by potential partners, which are shorter-term (not years). If results are confirmatory, partners may consider formal arrangements. Negotiations would follow successful evaluations.
Q:Are there metrics for a successful transition year for Nuvaxovid?
A:Success metrics include achieving a full U.S. license (BLA), competitive shelf life, and prefilled syringe approval. Sanofi's marketing and contracting capabilities are expected to optimize distribution and sales in the next cycle.
Q:What does Novavax think the clinical bar for success for a novel shingles vaccine is?
A:The current shingles vaccine has high efficacy but significant side effects, leading to missed booster shots. Novavax aims to address tolerability issues while maintaining competitive efficacy, leveraging its Matrix-M technology.
Q:Could you walk us through the $75 million milestone estimate for next year?
A:The $75 million milestone relates to completing manufacturing tech transfer with Sanofi by Q4 next year. This includes transitioning commercial manufacturing responsibilities to Sanofi.
Q:Is the supply sales piece essentially reimbursement for the COGS on Nuvaxovid production?
A:Yes, supply sales primarily cover costs with a small margin. This includes COVID vaccine supply for Sanofi and Matrix-M for partners. Production cycles align with seasonal demand to maximize shelf life.
Q:Is there guidance on the size of the government stockpile for the Sanofi pandemic effort?
A:No specific guidance on stockpile size. Novavax expanded its agreement with Sanofi to include Matrix-M in their pandemic flu vaccine, with terms to be negotiated if the program advances.
Q:Do you see duration of protection as an area for more clinical work for Nuvaxovid?
A:Real-world evidence studies are ongoing to assess durability of protection. These studies are conducted by third parties and results are expected in the future.
Q:What is the strategy behind Novavax's early-stage pipeline?
A:The strategy focuses on addressing significant unmet global health needs where Novavax's technology has competitive potential. The company aims to partner pipeline assets while maintaining flexibility to retain promising candidates.
Q:What are the primary areas for cost reduction in the 2027 expense projections?
A:Cost reductions stem from completing transition activities with Sanofi, including manufacturing support and clinical studies. The company targets a lean $250 million net spend while maintaining operational efficiency.
Q:Review of Unclear Management Responses
A:Management avoided providing specific guidance on the size of the government stockpile for the Sanofi pandemic effort, stating only that terms would be negotiated if the program advances. Additionally, they did not commit to specific timelines for Matrix-M evaluations converting to formal arrangements, citing variability in partner experiments and negotiations.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CIC program
Investors
Maryland site
Matrix adjuvant
Matrix malaria
Phase II
RD SGA
RD reimbursement
RD support
Slide
benefit
debt refinancing
decade
diff shingle
difference
increase
license partner
market year
meeting opportunity
need vaccination
net partner
noncash charge
partner reimbursement
preview
program diff
rate vaccine
reimbursement RD
royalty stream
shingle combination
site consolidation
source
strength cash
supply sale
transaction
transition
vaccination rate
NVAX Transcript
Novavax, Inc. (NVAX) Presents at Jefferies Global Healthcare Conference 2026 Transcript
Neutral6-4
Novavax, Inc. (NVAX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Neutral5-13
Novavax, Inc. (NVAX) Q1 2026 Earnings Call Transcript
Positive5-6
The earnings call summary highlights a 12% YoY revenue increase and improved net loss, reflecting strong financial performance. The strategic initiatives and partnerships indicate potential growth, while the cash increase suggests financial health. Despite regulatory and strategic risks, the overall outlook is optimistic. No negative sentiment from the Q&A section further supports a positive rating.
Novavax, Inc. (NVAX) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
NVAX Slides
NVAX Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
